Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma

F. J. Giles; E. N. McSweeney; J. D.M. Richards; J. S. Tobias; E. J. Gaminara; I. R. Grant; J. W. Kearney; A. C. Newland; N. E. Parker; S. Schey; A. H. Goldstone

doi:10.1016/0959-8049(92)90527-9

Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma

F. J. Giles, E. N. McSweeney, J. D.M. Richards, J. S. Tobias, E. J. Gaminara, I. R. Grant, J. W. Kearney, A. C. Newland, N. E. Parker, S. Schey, A. H. Goldstone

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

10 Citations (Scopus)

Abstract

Immediately before first hemi-body irradiation, 59 patients with relapsed multiple myeloma were randomised to receive or not to receive subsequent alpha-2b interferon maintenance. 13 patients (22%) [8 of 31 (26%) controls, 5 of 28 (18%) in the interferon arm] received single hemi-body irradiation alone due to progressive disease and/or persistent cytopoenias following the initial procedure. Mean time between upper and lower hemi-body irradiation was 69 days (range 35-294). Of 23 patients randomised to receive interferon and completing double hemi-body irradiation, 15 (65%) achieved peripheral blood counts adequate to allow interferon administration as per study criteria commencing at a mean 116 days (61-241) from time of study entry. The mean period of interferon therapy, starting at a mean 65 days (26-160) post second hemi-body irradiation, is 16.4 months (2-33.5). There was no significant difference in median survival durations (10 months) from time of initial radiotherapy between control and interferon patients.

Original language	English
Pages (from-to)	1392-1395
Number of pages	4
Journal	European Journal of Cancer
Volume	28
Issue number	8-9
DOIs	https://doi.org/10.1016/0959-8049(92)90527-9
Publication status	Published - 1992
Externally published	Yes

Access to Document

10.1016/0959-8049(92)90527-9

Cite this

Giles, F. J., McSweeney, E. N., Richards, J. D. M., Tobias, J. S., Gaminara, E. J., Grant, I. R., Kearney, J. W., Newland, A. C., Parker, N. E., Schey, S., & Goldstone, A. H. (1992). Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. European Journal of Cancer, 28(8-9), 1392-1395. https://doi.org/10.1016/0959-8049(92)90527-9

@article{d5457ee6436c44fb831364477cc0958f,

title = "Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma",

abstract = "Immediately before first hemi-body irradiation, 59 patients with relapsed multiple myeloma were randomised to receive or not to receive subsequent alpha-2b interferon maintenance. 13 patients (22%) [8 of 31 (26%) controls, 5 of 28 (18%) in the interferon arm] received single hemi-body irradiation alone due to progressive disease and/or persistent cytopoenias following the initial procedure. Mean time between upper and lower hemi-body irradiation was 69 days (range 35-294). Of 23 patients randomised to receive interferon and completing double hemi-body irradiation, 15 (65%) achieved peripheral blood counts adequate to allow interferon administration as per study criteria commencing at a mean 116 days (61-241) from time of study entry. The mean period of interferon therapy, starting at a mean 65 days (26-160) post second hemi-body irradiation, is 16.4 months (2-33.5). There was no significant difference in median survival durations (10 months) from time of initial radiotherapy between control and interferon patients.",

author = "Giles, {F. J.} and McSweeney, {E. N.} and Richards, {J. D.M.} and Tobias, {J. S.} and Gaminara, {E. J.} and Grant, {I. R.} and Kearney, {J. W.} and Newland, {A. C.} and Parker, {N. E.} and S. Schey and Goldstone, {A. H.}",

year = "1992",

doi = "10.1016/0959-8049(92)90527-9",

language = "English",

volume = "28",

pages = "1392--1395",

journal = "European Journal of Cancer",

issn = "0959-8049",

number = "8-9",

}

Giles, FJ, McSweeney, EN, Richards, JDM, Tobias, JS, Gaminara, EJ, Grant, IR, Kearney, JW, Newland, AC, Parker, NE, Schey, S & Goldstone, AH 1992, 'Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma', European Journal of Cancer, vol. 28, no. 8-9, pp. 1392-1395. https://doi.org/10.1016/0959-8049(92)90527-9

Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. / Giles, F. J.; McSweeney, E. N.; Richards, J. D.M. et al.
In: European Journal of Cancer, Vol. 28, No. 8-9, 1992, p. 1392-1395.

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

TY - JOUR

T1 - Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma

AU - Giles, F. J.

AU - McSweeney, E. N.

AU - Richards, J. D.M.

AU - Tobias, J. S.

AU - Gaminara, E. J.

AU - Grant, I. R.

AU - Kearney, J. W.

AU - Newland, A. C.

AU - Parker, N. E.

AU - Schey, S.

AU - Goldstone, A. H.

PY - 1992

Y1 - 1992

N2 - Immediately before first hemi-body irradiation, 59 patients with relapsed multiple myeloma were randomised to receive or not to receive subsequent alpha-2b interferon maintenance. 13 patients (22%) [8 of 31 (26%) controls, 5 of 28 (18%) in the interferon arm] received single hemi-body irradiation alone due to progressive disease and/or persistent cytopoenias following the initial procedure. Mean time between upper and lower hemi-body irradiation was 69 days (range 35-294). Of 23 patients randomised to receive interferon and completing double hemi-body irradiation, 15 (65%) achieved peripheral blood counts adequate to allow interferon administration as per study criteria commencing at a mean 116 days (61-241) from time of study entry. The mean period of interferon therapy, starting at a mean 65 days (26-160) post second hemi-body irradiation, is 16.4 months (2-33.5). There was no significant difference in median survival durations (10 months) from time of initial radiotherapy between control and interferon patients.

AB - Immediately before first hemi-body irradiation, 59 patients with relapsed multiple myeloma were randomised to receive or not to receive subsequent alpha-2b interferon maintenance. 13 patients (22%) [8 of 31 (26%) controls, 5 of 28 (18%) in the interferon arm] received single hemi-body irradiation alone due to progressive disease and/or persistent cytopoenias following the initial procedure. Mean time between upper and lower hemi-body irradiation was 69 days (range 35-294). Of 23 patients randomised to receive interferon and completing double hemi-body irradiation, 15 (65%) achieved peripheral blood counts adequate to allow interferon administration as per study criteria commencing at a mean 116 days (61-241) from time of study entry. The mean period of interferon therapy, starting at a mean 65 days (26-160) post second hemi-body irradiation, is 16.4 months (2-33.5). There was no significant difference in median survival durations (10 months) from time of initial radiotherapy between control and interferon patients.

UR - http://www.scopus.com/inward/record.url?scp=0026681863&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(92)90527-9

DO - 10.1016/0959-8049(92)90527-9

M3 - Article

C2 - 1515255

AN - SCOPUS:0026681863

SN - 0959-8049

VL - 28

SP - 1392

EP - 1395

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 8-9

ER -

Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this